Suppr超能文献

随着时间的推移,比较 Tet2 催化缺陷型和敲除型骨髓。

Comparative analysis of Tet2 catalytic-deficient and knockout bone marrow over time.

机构信息

Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY; Department of Genetics, Albert Einstein College of Medicine, Bronx, NY; Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY.

Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, Bronx, NY; Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY; Departments of Oncology and Medicine, Albert Einstein College of Medicine-Montefiore Health System, Bronx, NY; Montefiore Einstein Cancer Center, Bronx, NY.

出版信息

Exp Hematol. 2023 Aug;124:45-55.e2. doi: 10.1016/j.exphem.2023.05.004. Epub 2023 May 22.

Abstract

TET2 is a member of the Ten-eleven translocation (Tet) family of DNA dioxygenases that regulate gene expression by promoting DNA demethylation (enzymatic activity) and partnering with chromatin regulatory complexes (nonenzymatic functions). TET2 is highly expressed in the hematopoietic lineage, where its molecular functions are the subject of continuous investigations because of the prevalence of TET2 mutations in hematologic malignancies. Previously, we have implicated Tet2 catalytic and noncatalytic functions in the regulation of myeloid and lymphoid lineages, respectively. However, the impact of these functions of Tet2 on hematopoiesis as the bone marrow ages remains unclear. Here, we conducted comparative transplantations and transcriptomic analyses of 3-, 6-, 9-, and 12-month-old Tet2 catalytic mutant (Mut) and knockout (KO) bone marrow. Tet2 Mut bone marrow of all ages exclusively caused hematopoietic disorders of the myeloid lineage. In contrast, young Tet2 KO bone marrow developed both lymphoid and myeloid diseases, whereas older Tet2 KO bone marrow predominantly elicited myeloid disorders with shorter latency than age-matched Tet2 Mut bone marrow. We identified robust gene dysregulation in Tet2 KO Lin cells at 6 months that involved lymphoma and myelodysplastic syndrome and/or leukemia-causing genes, many of which were hypermethylated early in life. There was a shift from lymphoid to myeloid gene deregulation in Tet2 KO Lin cells with age, underpinning the higher incidence of myeloid diseases. These findings expand on the dynamic regulation of bone marrow by Tet2 and show that its catalytic-dependent and -independent roles have distinct impacts on myeloid and lymphoid lineages with age.

摘要

TET2 是 Ten-eleven 易位(Tet)家族的 DNA 双加氧酶成员,通过促进 DNA 去甲基化(酶活性)并与染色质调节复合物(非酶活性)合作来调节基因表达。TET2 在造血谱系中高度表达,由于 TET2 突变在血液恶性肿瘤中的普遍性,其分子功能是不断研究的主题。先前,我们已经分别暗示 Tet2 催化和非催化功能在髓系和淋巴谱系的调节中。然而,随着骨髓老化,Tet2 的这些功能对造血的影响仍不清楚。在这里,我们对 3、6、9 和 12 个月大的 Tet2 催化突变(Mut)和敲除(KO)骨髓进行了比较移植和转录组分析。所有年龄段的 Tet2 Mut 骨髓仅导致骨髓髓系造血紊乱。相比之下,年轻的 Tet2 KO 骨髓既发展为淋巴系疾病,也发展为髓系疾病,而较老的 Tet2 KO 骨髓主要引起髓系疾病,潜伏期比同龄的 Tet2 Mut 骨髓短。我们在 6 个月时鉴定了 Tet2 KO Lin 细胞中稳健的基因失调,涉及淋巴瘤和骨髓增生异常综合征和/或白血病致病基因,其中许多基因在生命早期就被高度甲基化。随着年龄的增长,Tet2 KO Lin 细胞中的基因失调从淋巴系向髓系转移,这支持了髓系疾病发病率较高的原因。这些发现扩展了 Tet2 对骨髓的动态调节,并表明其依赖于催化和非依赖于催化的作用对髓系和淋巴系随着年龄的增长具有不同的影响。

相似文献

1
Comparative analysis of Tet2 catalytic-deficient and knockout bone marrow over time.
Exp Hematol. 2023 Aug;124:45-55.e2. doi: 10.1016/j.exphem.2023.05.004. Epub 2023 May 22.
2
Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis.
Cell Rep. 2019 Sep 3;28(10):2480-2490.e4. doi: 10.1016/j.celrep.2019.07.094.
3
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.
Leukemia. 2014 Mar;28(3):485-96. doi: 10.1038/leu.2013.337. Epub 2013 Nov 13.
4
A zebrafish model of myelodysplastic syndrome produced through tet2 genomic editing.
Mol Cell Biol. 2015 Mar;35(5):789-804. doi: 10.1128/MCB.00971-14. Epub 2014 Dec 15.
5
[TET2 gene in hematological diseases].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Jun;22(3):836-41. doi: 10.7534/j.issn.1009-2137.2014.03.049.
6
TET proteins and 5-methylcytosine oxidation in hematological cancers.
Immunol Rev. 2015 Jan;263(1):6-21. doi: 10.1111/imr.12239.
7
Stress hematopoiesis induces a proliferative advantage in TET2 deficiency.
Leukemia. 2022 Mar;36(3):809-820. doi: 10.1038/s41375-021-01427-7. Epub 2021 Sep 30.
8
Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis.
J Exp Clin Cancer Res. 2022 Oct 7;41(1):294. doi: 10.1186/s13046-022-02496-x.
10
TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
Cancer Sci. 2014 Sep;105(9):1093-9. doi: 10.1111/cas.12484. Epub 2014 Sep 3.

引用本文的文献

1
TET3 regulates hematopoietic stem cell homeostasis during embryonic and adult hematopoiesis.
Hemasphere. 2025 May 6;9(5):e70140. doi: 10.1002/hem3.70140. eCollection 2025 May.

本文引用的文献

1
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment.
Cancer Cell. 2023 Feb 13;41(2):323-339.e10. doi: 10.1016/j.ccell.2023.01.003. Epub 2023 Feb 2.
2
Tet1 Suppresses p21 to Ensure Proper Cell Cycle Progression in Embryonic Stem Cells.
Cells. 2022 Apr 17;11(8):1366. doi: 10.3390/cells11081366.
3
NPM1 ablation induces HSC aging and inflammation to develop myelodysplastic syndrome exacerbated by p53 loss.
EMBO Rep. 2022 May 4;23(5):e54262. doi: 10.15252/embr.202154262. Epub 2022 Mar 1.
5
Gene mutation spectrum of patients with myelodysplastic syndrome and progression to acute myeloid leukemia.
Int J Hematol Oncol. 2021 Jun 22;10(2):IJH34. doi: 10.2217/ijh-2021-0002. eCollection 2021 Jun.
6
Non-catalytic Roles of Tet2 Are Essential to Regulate Hematopoietic Stem and Progenitor Cell Homeostasis.
Cell Rep. 2019 Sep 3;28(10):2480-2490.e4. doi: 10.1016/j.celrep.2019.07.094.
7
TET2 binding to enhancers facilitates transcription factor recruitment in hematopoietic cells.
Genome Res. 2019 Apr;29(4):564-575. doi: 10.1101/gr.239277.118. Epub 2019 Feb 22.
8
TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis.
Cancer Discov. 2018 Dec;8(12):1632-1653. doi: 10.1158/2159-8290.CD-18-0657. Epub 2018 Oct 1.
9
B-cell tumor development in -deficient mice.
Blood Adv. 2018 Mar 27;2(6):703-714. doi: 10.1182/bloodadvances.2017014118.
10
Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Cell. 2017 Oct 5;171(2):481-494.e15. doi: 10.1016/j.cell.2017.09.027.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验